Brief: Hansa Biopharma Says Entered Into Agreement With AskBio To Evaluate Feasibility Of Imlifidase As Pre-Treatment Ahead Of Gene Therapy In Pompe Disease
03/01/2022 17:39
Jan 3 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA ENTERS INTO AGREEMENT WITH ASKBIO TO
EVALUATE
FEASIBILITY OF IMLIFIDASE AS PRE-TREATMENT AHEAD OF GENE THERAPY
IN POMPE DISEASE
* HANSA WILL RECEIVE A USD 5 MILLION PAYMENT UPON EXECUTION
OF
AGREEMENT
* ASKBIO WILL HAVE AN EXCLUSIVE OPTION TO ENTER INTO A FULL
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
Source text for Eikon: ID:nWkr4bjyh8
Further company coverage: HNSA.ST
((reuters.briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS